Biosimilar ‘uptake drivers’ that encourage prescribing of biosimilars over originator biologics will be applied universally and not just to the brand that makes an application for them, the federal government has confirmed. The Pharmaceutical Benefits Advisory Committee (PBAC) has set out its position on uptake measures such as lower authority levels in newly-released documents covering the ...
Biosimilar uptake drivers will apply to all brands, PBAC confirms
By Tessa Hoffman
9 Mar 2018